ASX
LCT 0.047    Last updated 1.14 am
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

The following fact sheets provide a summary of our current business and research pipeline.

Cell therapy for neurodegenerative diseases

Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which restore function using naturally occurring cells.

 

LCT’s lead product NTCELL® is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation, NTCELL functions as a biological factory producing nerve growth factors to promote new central nervous system growth and repair disease induced nerve degeneration.

 

The Phase I/IIa NTCELL clinical trial in New Zealand for the treatment of Parkinson’s disease met the primary endpoint of safety and showed encouraging clinical efficacy improvements. Results from this trial will be used to design a larger Phase IIb trial to evaluate its potential as a disease-modifying treatment for patients with Parkinson’s disease. It has the potential to be used in a number of other central nervous system indications such as Huntington’s, Alzheimer’s and motor neurone diseases.

 

LCT’s proprietary encapsulation technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system. 

 

LCT holds a 50% interest in Diatranz Otsuka Limited which is developing a cell therapy for type 1 diabetes.

 

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand.

 

— 27 July 2015

Appendix 4C Quarterly Report 30 June 2015

Living Cell Technologies Limited today released its cash flow report for the quarter ended 30 June 2015. The company ended the quarter with a cash balance of $5,144,027 compared to $6,349,884 in the previous quarter.

Read More Read Less

— 14 July 2015

Proposed grant of options to directors

Directors will be seeking shareholder approval at the AGM later in 2015 to the grant of options to purchase shares in the Company and which forms part of their remuneration. Remunerating Directors in this manner aligns their interests more closely with that of all shareholders and reduces the cash cost to the Company.

Read More Read Less
Load More

— 8 May 2014

Please refer to our news releases

Load More
— 15 June 2015

International Congress of Parkinson's Disease and Movement Disorders. "Safety and clinical effects of NTCELL® in patients with Parkinson's disease: 26 weeks follow-up." 12:30 - 14:00 Coronado Ballroom (Level 4) Manchester Grand Hyatt San Diego 1 Market Place San Diego, California, USA, 92101

— 18 June

Investor call to discuss NTCELL clinical study results. LCT CEO Ken Taylor and Principal Investigator Dr Barry Snow will host an investor call to discuss the results of the Phase I/IIa clinical study of NTCELL in Parkinson's disease. Date: Thursday 18 June 2015 Time: NZT 10.30am, AEST 8.30am, PDT 3.30pm (17 June) Conference ID: 6398 0894 Toll-free dial-in numbers for participants: Australia - 1800 123 296 New Zealand - 0800 452 782 Canada - 1855 5616 766 China - 4001 203 085 Hong - Kong 800 908 865 India - 1800 3010 6141 Japan - 0120 985 190 Singapore - 800 616 2288 United Kingdom - 0808 234 0757 United States - 1855 293 1544 or toll +61 2 8038 5221

— 10 November 2015

LCT Annual General Meeting. To be held in Auckland, New Zealand.

Load More
Announcements

— 27 July 2015

Appendix 4C Quarterly Report 30 June 2015

Living Cell Technologies Limited today released its cash flow report for the quarter ended 30 June 2015. The company ended the quarter with a cash balance of $5,144,027 compared to $6,349,884 in the previous quarter.

Read More Read Less

— 14 July 2015

Proposed grant of options to directors

Directors will be seeking shareholder approval at the AGM later in 2015 to the grant of options to purchase shares in the Company and which forms part of their remuneration. Remunerating Directors in this manner aligns their interests more closely with that of all shareholders and reduces the cash cost to the Company.

Read More Read Less
Load More
LCT in the News

— 8 May 2014

Please refer to our news releases

Load More
Events
— 15 June 2015

International Congress of Parkinson's Disease and Movement Disorders. "Safety and clinical effects of NTCELL® in patients with Parkinson's disease: 26 weeks follow-up." 12:30 - 14:00 Coronado Ballroom (Level 4) Manchester Grand Hyatt San Diego 1 Market Place San Diego, California, USA, 92101

— 18 June

Investor call to discuss NTCELL clinical study results. LCT CEO Ken Taylor and Principal Investigator Dr Barry Snow will host an investor call to discuss the results of the Phase I/IIa clinical study of NTCELL in Parkinson's disease. Date: Thursday 18 June 2015 Time: NZT 10.30am, AEST 8.30am, PDT 3.30pm (17 June) Conference ID: 6398 0894 Toll-free dial-in numbers for participants: Australia - 1800 123 296 New Zealand - 0800 452 782 Canada - 1855 5616 766 China - 4001 203 085 Hong - Kong 800 908 865 India - 1800 3010 6141 Japan - 0120 985 190 Singapore - 800 616 2288 United Kingdom - 0808 234 0757 United States - 1855 293 1544 or toll +61 2 8038 5221

— 10 November 2015

LCT Annual General Meeting. To be held in Auckland, New Zealand.

Load More
© 2015 Living Cell Technologies Limited.
site by { brownpaperbag }